An experimental regenerative therapy that Frequency Therapeutics was developing to treat a form of hearing loss has failed to beat a placebo in a clinical trial for the second time in two years, ...

Frequency Therapeutics is going back to the drawing board. After showing promise in phase 1, four dosing regimens of its hearing loss treatment did no better than placebo in a phase 2a study. The ...

WOBURN, Mass.--(BUSINESS WIRE)-- Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused ...

U.S. stock futures were lower this morning, with the Dow futures falling around 300 points on Friday. Shares of Frequency Electronics, Inc. (NASDAQ:FEIM) fell sharply in today's pre-market trading ...